Cancer suffer's victory prompts discussions on additional private drugs
The insurance industry should begin discussing the possible implications of the debate over cancer drugs, according to the Association of British Insurers (ABI). The body outlined its stance following September's victory in court for Colin Ross, a cancer sufferer who took West Sussex Primary Care Trust (PCT) to court in order to force them to supply him with the drug Revlimid. Despite the medication being prescribed in other areas, West Sussex PCT refused to supply the medication. The ABI, in anticipation of the Richards Review into the consequences of additional private drugs for NHS c...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
